Abstract #0483

Imaging Modulation of Tumor Hypoxia in vivo Using a Nitroimidazole Based T1 MR Contrast Agent

Praveen Gulaka¹, Robert Trokowski², Ralph P. Mason³, Dean Sherry², Vikram D. Kodibagkar,¹⁴

¹Joint Program in Biomedical Engineering, UT Arlington/UT Southwestern Medical Center, Dallas, TX, United States; ²Advanced Imaging Research Center, UT Southwestern Medical Center, Dallas, TX, United States; ³Radiology, UT Southwestern Medical Center, Dallas, TX, United States; ⁴School of Biological and Health Systems Engineering, Arizona State University, Tempe, AZ, United States

Hypoxia in tumors is known to affect radiation sensitivity and promote development of metastases. Therefore the ability to image tumor hypoxia in vivo could provide useful prognostic information and help tailor therapy. Previous research demonstrated In Vitro and in vivo evidence for selective accumulation of a T1 shortening agent, a GdDOTA monoamide conjugate of 2-nitroimidazole (abbreviated as GdDO3NI), under hypoxia. In this work, we report differential response of tumor hypoxia to oxygen breathing in two prostate cancer sublines (AT1 and HI) of rat prostate adenocarcinoma as imaged using GdDO3NI, thus, showing utility in stratifying tumor response to hypoxia altering interventions.